[ { "id": 1655, "name": "PreDxion Bio", "slug": "predxion-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/519a74fb089a6c9dd854328b8022c68e00467972.png", "website": "http://www.predxionbio.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale.\r\n\r\nPreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.", "one_liner": "Rapid, scalable diagnostic for SARS-CoV-2 and beyond", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493740320, "tags": [ "Microfluidics", "Nanosensors", "COVID-19" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/predxion-bio", "api": "https://yc-oss.github.io/api/batches/summer-2017/predxion-bio.json" }, { "id": 1773, "name": "Persephone Biosciences", "slug": "persephone-biosciences", "former_names": [ "Persephone Biome" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/23a03009ea76f97d455fc7ac751ee2643dbe4591.png", "website": "http://persephonebiosciences.com/", "all_locations": "San Diego, CA, USA", "long_description": "Persephone Biome develops live biotherapeutic products to modulate the metabolism of gut microbes, for applications in disease prevention and cure. We take a unique engineering approach using systems and synthetic biology to understand the complexities of the microbiome.", "one_liner": "We are using the gut microbiome to end cancer. ", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509678246, "tags": [ "AI-powered Drug Discovery", "COVID-19" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/persephone-biosciences", "api": "https://yc-oss.github.io/api/batches/winter-2018/persephone-biosciences.json" }, { "id": 13332, "name": "PostEra", "slug": "postera", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6f01f8ef89abde929fff3e9924c177906b679828.png", "website": "https://postera.ai/", "all_locations": "Boston, MA, USA", "long_description": "PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discovery effort; COVID Moonshot.", "one_liner": "Medicinal Chemistry powered by Machine Learning", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1584128465, "tags": [ "AI-powered Drug Discovery", "Machine Learning", "COVID-19" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/postera", "api": "https://yc-oss.github.io/api/batches/winter-2020/postera.json" }, { "id": 25285, "name": "Scout", "slug": "scout-2", "former_names": [ "Uh-Oh Labs", "Scout (formerly Uh-Oh Labs)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/aef2a50967bbb0e1e0f4bc9ebba4727befed3822.png", "website": "http://scouthealth.com", "all_locations": "San Francisco, CA, USA", "long_description": "Digital health holds a lot of potential but is ignoring a growing problem: diagnostic testing. Without this data, providers and organizations will be limited in the services they can provide patients at home.\r\n\r\nScout has developed a platform - Hub, test kits, and app - that delivers health testing at home with 10x lower development cost and 3x lower per-test price. Our patented tech also meets performance requirements for medical diagnoses and integrates with the current healthcare tech stack. Scout’s technology is poised to disrupt the outdated $33Bn diagnostic market by democratizing testing while dramatically improving the patient experience.\r\n\r\nScout has received $16M in non-dilutive funding from the NIH and other organizations to fully de-risk our platform, and our pipeline includes a diverse test menu for primary care (e.g. respiratory and sexual health), wellness (e.g. gut health), and chronic conditions (e.g. certain cancers). We have already received FDA authorization for our platform in clinical settings and are planning to launch our flagship Scout Hub in 2024.", "one_liner": "The smart testing platform that unlocks digital health at home.", "team_size": 12, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1645122247, "tags": [ "Consumer Health Services", "COVID-19", "Health Tech", "Diagnostics", "Consumer Products" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/scout-2", "api": "https://yc-oss.github.io/api/batches/winter-2022/scout-2.json" } ]